Phosphodiesterase IV inhibitor - Celltech/Merck
Alternative Names: PDE4 inhibitor - Celltech/MerckLatest Information Update: 21 Sep 2007
At a glance
- Originator Celltech Group
- Developer Merck & Co
- Class
- Mechanism of Action Type 4 cyclic nucleotide phosphodiesterase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Asthma; Chronic obstructive pulmonary disease
Most Recent Events
- 21 Jul 2003 Phase-I clinical trials in Asthma in USA (PO)
- 21 Jul 2003 Phase-I clinical trials in Chronic obstructive pulmonary disease in USA (PO)
- 08 May 2003 Discontinued - Phase-II for Asthma in USA (PO)